PALISADE BIO, INC. Annual Share-based Payment Arrangement, Expense in USD from 2013 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Palisade Bio, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2013 to 2023.
  • Palisade Bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $358K, a 149% increase year-over-year.
  • Palisade Bio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $840K, a 46.1% increase year-over-year.
  • Palisade Bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $606K, a 41.3% decline from 2022.
  • Palisade Bio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.03M, a 45.4% decline from 2021.
  • Palisade Bio, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1.89M, a 6.11% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $606K -$426K -41.3% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-26
2022 $1.03M -$859K -45.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-26
2021 $1.89M -$123K -6.11% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-22
2020 $2.01M +$1.13M +129% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 $881K +$247K +38.9% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-22
2018 $634K -$1.14M -64.2% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-27
2017 $1.77M -$1.68M -48.6% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-22
2016 $3.45M +$494K +16.7% Jan 1, 2016 Dec 31, 2016 10-K 2018-04-02
2015 $2.95M -$1.37M -31.7% Jan 1, 2015 Dec 31, 2015 10-K 2017-03-23
2014 $4.32M +$1.99M +85.3% Jan 1, 2014 Dec 31, 2014 10-K 2016-03-14
2013 $2.33M Jan 1, 2013 Dec 31, 2013 10-K 2016-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.